{"gene":"CHRNA5","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2011,"finding":"CHRNA5 acts as a negative regulator of nicotine signaling in bronchial cells: siRNA-mediated silencing of CHRNA5, or pharmacological inhibition with α-conotoxin MII, increased cell motility, invasiveness, and calcium influx in both non-transformed bronchial cells and lung cancer cell lines, mimicking the effect of nicotine. These effects were blocked by inhibiting CHRNA7 (α7 nAChR). Silencing CHRNA5 also decreased expression of cell adhesion molecules P120 and ZO-1 in lung cancer cells and reduced DeltaNp63α expression in squamous cell carcinoma lines.","method":"siRNA knockdown, pharmacological inhibition (α-conotoxin MII), in vitro motility/invasion assays, calcium influx measurement, western blot for adhesion molecules","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RNAi, pharmacological antagonism, functional assays) in a single lab; consistent results across cell types","pmids":["21586512"],"is_preprint":false},{"year":2010,"finding":"ASCL1 transcription factor regulates expression of the CHRNA5/A3/B4 gene cluster in small-cell lung carcinoma (SCLC): knockdown of ASCL1 in SCLC cells significantly decreased expression of the α3 and β4 nAChR subunit genes without affecting other highly expressed nAChR genes, and without effect in non-SCLC lines. The clustered nAChR genes (CHRNA5, CHRNA3, CHRNB4) are coordinately overexpressed in SCLC and contain putative ASCL1 binding sites in their promoters.","method":"Quantitative RT-PCR in lung cancer cell lines and patient samples; siRNA knockdown of ASCL1; in silico promoter analysis","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct loss-of-function knockdown with specific gene-expression readout in multiple cell lines; single lab, two complementary methods","pmids":["20124469"],"is_preprint":false},{"year":2010,"finding":"Promoter haplotypes of CHRNA5 significantly regulate its mRNA transcript levels in human lung tissue. The delTTC promoter haplotype was associated with the highest CHRNA5 transcript levels, while the insTGG haplotype (linked to risk alleles for nicotine dependence, lung cancer, and COPD) was associated with the lowest transcript levels. Luciferase reporter assays in human lung cancer cell lines confirmed that 5' promoter haplotypes significantly altered CHRNA5 promoter activity, while 3'-UTR variants did not.","method":"Quantitative RT-PCR on human lung tissue from 68 patients; luciferase reporter assays in four human lung cancer cell lines (A549, H460, H520, H596)","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional reporter assay plus ex vivo mRNA quantification in human tissue, replicated across multiple cell lines; two independent orthogonal methods in one study","pmids":["20733116"],"is_preprint":false},{"year":2011,"finding":"CHRNA5 promoter variants affect allelic expression: luciferase reporter assays showed that deletion at rs3841324 combined with variation at rs503464 decreased CHRNA5 promoter-derived activity, potentially by loss of an SP-1 binding site. Variations within the CHRNA5 5'UTR (rs55853698 and rs55781567) also altered luciferase expression. A distal promoter region was found to strongly repress CHRNA5 transcription.","method":"Luciferase reporter assays in BE(2)-C neuroblastoma cells; allelic expression imbalance (AEI) analysis in post-mortem brain tissue; heterologous promoter constructs","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — functional reporter assay with mutagenesis-like variant analysis plus ex vivo AEI; single lab, multiple orthogonal methods","pmids":["21858091"],"is_preprint":false},{"year":2013,"finding":"Cis-regulatory variants in the CHRNA5-CHRNA3-CHRNB4 region exert a direct cis-regulatory effect on CHRNA5 transcript levels in human frontal cortex. Quantitative allele-specific expression analysis in African-American (n=49) and European-American (n=111) brain samples identified 10 highly correlated variants in a 9 kb region as potential functional variants modifying CHRNA5 mRNA expression levels.","method":"Quantitative allele-specific gene expression (ASE) in post-mortem human frontal cortex from subjects of African and European ancestry","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cis-regulatory measurement in human brain tissue using ASE, two ancestral populations as internal replication; single lab","pmids":["24303001"],"is_preprint":false},{"year":2015,"finding":"The intronic CHRNB4 SNP rs11636753 is associated with CHRNA5 DNA methylation levels in multiple human brain regions (prefrontal cortex, frontal cortex, temporal cortex, pons). The rs11636753 major (G) allele was associated with lower CHRNA5 DNA methylation, lower CHRNA5 mRNA expression, and increased nicotine dependence risk. Haplotype analysis showed rs11636753-G and rs16969968-A alleles together increased nicotine dependence risk more than either alone, connecting methylation differences to mRNA expression and dependence risk.","method":"cis-meQTL analysis using SNP genotypes and DNA methylation in post-mortem brain (BrainCloud and Brain QTL cohorts, N=240); expression analysis; haplotype association in five independent cohorts (N=11,096)","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — meQTL replicated across four brain regions and five independent cohorts; multiple orthogonal methods (methylation, mRNA, dependence phenotype) connecting mechanism to phenotype","pmids":["26220977"],"is_preprint":false},{"year":2018,"finding":"In the mouse interpeduncular nucleus (IPN), α5-null (Chrna5 knockout) mice show markedly reduced electrophysiological responses to nicotinic acetylcholine receptor stimulation. Chrna5-expressing IPN neurons are GABAergic and project to mesopontine raphe and tegmentum. Optogenetic stimulation of Chrna5-expressing IPN neurons is aversive, but only after priming by recent prior stimulation or nicotine exposure. The Chrna5Cre transgenic mice revealed that Chrna5 transcription is regulated independently from the Chrna3/b4 genes transcribed on the opposite strand.","method":"Electrophysiology in α5-null mice; BAC recombineering to generate Chrna5Cre transgenic mice; optogenetics; reporter-based circuit tracing; immunohistochemistry","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (electrophysiology, optogenetics, transgenic mice, circuit anatomy) in a single rigorous study; direct mechanistic readout","pmids":["29954848"],"is_preprint":false},{"year":2018,"finding":"Transgenic rats expressing the human CHRNA5 risk polymorphism (rs16969968, D398N, α5SNP) self-administer more nicotine at high doses and exhibit higher nicotine-induced reinstatement of nicotine seeking than wild-type rats. IPN neurons of α5SNP rats showed altered reactivity to nicotine electrophysiologically, linking the IPN circuit to the higher relapse phenotype.","method":"Zinc finger nuclease-generated knock-in rats; intravenous nicotine self-administration; reinstatement paradigm; ex vivo electrophysiology of IPN neurons","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — knock-in rat model with specific human variant, complemented by electrophysiology and behavioral paradigms; multiple orthogonal methods in one study","pmids":["30293722"],"is_preprint":false},{"year":2011,"finding":"Transgenic mice overexpressing the human CHRNA5/A3/B4 genomic cluster showed increased functional α3β4-nAChRs in brain regions where these subunits are normally expressed, increased sensitivity to pharmacological effects of nicotine, higher activation of the medial habenula and reduced activation of dopaminergic VTA neurons after acute nicotine, and increased acquisition of nicotine self-administration with a differential response in a progressive ratio test.","method":"BAC transgenic mouse overexpression; radioligand binding for α3β4-nAChRs; pharmacological nicotine challenge; c-Fos immunostaining; nicotine self-administration; progressive ratio test","journal":"Amino acids","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic gain-of-function model with multiple orthogonal behavioral and neurobiological readouts; in vivo mechanistic study","pmids":["22101982"],"is_preprint":false},{"year":2016,"finding":"iPSC-derived human dopaminergic and glutamatergic neurons carrying the CHRNA5 N398 risk allele (rs16969968) showed increased excitatory postsynaptic current responses to nicotine compared to D398 neurons. N398 glutamatergic neurons responded to lower nicotine doses (0.1 μM) with greater frequency and amplitude but also exhibited rapid desensitization, consistent with prior functional characterizations of the N398-associated receptor.","method":"iPSC differentiation to dopaminergic and glutamatergic neurons from homozygous D398 or N398 donors; whole-cell electrophysiology; gene expression profiling","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — functional electrophysiology in human iPSC-derived neurons with isogenic-like genotype comparison; two neuron types tested; single lab, multiple methods","pmids":["27698409"],"is_preprint":false},{"year":2020,"finding":"Chrna5 is essential for the rapid onset of postsynaptic cholinergic responses in prefrontal cortex layer VI corticothalamic neurons: optogenetic stimulation of cholinergic afferents in Chrna5 knockout mice showed slowed and delayed nicotinic excitation compared to wild-type. Chrna5 also protects nicotinic responses against desensitization under sustained stimulation conditions. An agonist for the α-α nicotinic binding site (NS9283) allosterically restored the rapid-onset kinetics without triggering desensitization.","method":"Optogenetics combined with ex vivo electrophysiology in compound-transgenic Chrna5 knockout and wild-type mice; two independent optogenetic mouse lines; pharmacological rescue with NS9283","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Strong — optogenetics + electrophysiology in two independent transgenic lines with genetic knockout and pharmacological rescue; multiple orthogonal approaches in one rigorous study","pmids":["32817066"],"is_preprint":false},{"year":2013,"finding":"Chrna5 genotype determines the lasting effects of developmental in vivo nicotine exposure on prefrontal cortex layer VI neuron morphology and nAChR currents: in wildtype mice, developmental nicotine exposure produced an immature morphological phenotype (apical dendrite morphology) and reduced nAChR currents persisting into adulthood; in α5(-/-) mice, developmental nicotine tended to normalize adult morphology and nAChR currents. Thus α5 subunit incorporation into α4β2* nAChRs in prefrontal layer VI mediates the direction of nicotine teratogenesis.","method":"In vivo developmental nicotine exposure in wildtype and Chrna5 knockout mice; patch-clamp electrophysiology; morphometric analysis of prefrontal layer VI neurons","journal":"Neuropharmacology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout combined with developmental exposure, electrophysiology and morphometry; multiple readouts; single lab","pmids":["24055499"],"is_preprint":false},{"year":2019,"finding":"Chrna5-expressing neurons in the prefrontal cortex include a distinct population of acetylcholine super-responders with subplate identity. Single-cell transcriptomics revealed that Chrna5+ super-responders uniquely express GPI-anchored lynx prototoxin genes (Lypd1, Ly6g6e, Lypd6b), predicting distinct regulation of nicotinic receptors. Pharmacological manipulation of lynx regulation was developed from transcriptomic predictions.","method":"Complex transgenic Chrna5Cre mice; opto-physiological experiments; single-cell RNA sequencing; pharmacological manipulation","journal":"iScience","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — transgenic mouse opto-physiology combined with single-cell transcriptomics and pharmacology; multiple orthogonal methods in one study","pmids":["36798433"],"is_preprint":false},{"year":2019,"finding":"Transgenic rats expressing the human CHRNA5 α5SNP (rs16969968) consumed more alcohol and exhibited increased relapse to alcohol seeking after abstinence. Higher relapse to alcohol was associated with altered neuronal activity in the insula (measured by c-Fos immunostaining). Relapse to food seeking was also increased in α5SNP transgenic rats, and nicotine treatment reduced relapse in both transgenic and control rats.","method":"Transgenic knock-in rats (α5SNP); alcohol self-administration; reinstatement paradigm; c-Fos immunostaining; food seeking assay; nicotine treatment","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — knock-in rat model with specific human variant; multiple behavioral paradigms and circuit-level readout; single lab","pmids":["31288250"],"is_preprint":false},{"year":2001,"finding":"The genomic structure of CHRNA5 was determined: the gene contains multiple exons, and its 3'-UTR region partially overlaps in a tail-to-tail configuration with the 3'-UTR of CHRNA3 due to two previously unknown introns in CHRNA3. Four novel intragenic polymorphisms were identified and characterized in the CHRNA5/A3/B4 cluster.","method":"Genomic sequencing; exon-intron structure analysis; polymorphism identification","journal":"Journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct sequence-based determination of genomic structure; foundational structural characterization; single lab","pmids":["11721883"],"is_preprint":false},{"year":2015,"finding":"The CHRNA5 rs16969968 A (N398) risk allele in humans was associated with significantly lower ratings of aversive effects of intravenous nicotine (P<5×10⁻⁸), with marked specificity over pleasurable and stimulatory effects. The risk allele was also associated with greater improvement on the Stroop cognitive control task following nicotine administration. This effect was replicated in both European-American and African-American subjects.","method":"Intravenous nicotine challenge in human subjects (n=192); subjective ratings of nicotine effects; Stroop cognitive task; genotype-stratified analysis","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — controlled IV nicotine challenge in humans with two independent ancestry groups as internal replication; genome-wide significant p-value; multiple behavioral readouts","pmids":["25948103"],"is_preprint":false},{"year":2018,"finding":"The CHRNA5 D398N variant interacts with developmental nicotine exposure in mice: offspring of dams exposed to nicotine during development showed genotype-dependent differences in nicotine intake at weaning; N Nic (N398 + developmental nicotine) offspring consumed the most nicotine at the highest concentration, while D Nic (D398 + developmental nicotine) offspring consumed the least. Nicotine-stimulated dopamine release from striatal synaptosomes was increased in D Nic offspring but decreased in N Nic offspring relative to genotype-matched controls.","method":"Two-bottle choice nicotine consumption test; synaptosome nicotine-stimulated dopamine release assay; developmental nicotine exposure paradigm; D398N knock-in mice","journal":"Genes, brain, and behavior","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knock-in mouse model with gene-environment interaction design; behavioral and neurochemical readouts; single lab","pmids":["29573323"],"is_preprint":false},{"year":2024,"finding":"Nicotine activates CHRNA5 in head and neck squamous cell carcinoma (HNSC) cells to promote proliferation, migration, and invasion. CHRNA5 knockdown reduced these effects, while nicotine reversed them. CHRNA5 activation by nicotine regulates CES1 expression and downstream MEK/ERK signaling: CHRNA5 knockdown decreased p-MEK/MEK, p-ERK/ERK, and CES1 protein levels. Co-immunoprecipitation and molecular docking confirmed a physical interaction between CHRNA5 and CES1. Tumor formation was reduced in nude mice using sh-CHRNA5 Cal27 cells.","method":"CCK-8 proliferation assay; wound healing and Transwell migration/invasion assays; siRNA knockdown and overexpression; immunofluorescence; co-immunoprecipitation; molecular docking; western blot for MEK/ERK; transcriptomics/pathway enrichment; in vivo tumor formation assay; IHC in patient tissues","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods; single lab; co-IP and in vivo tumor assay support mechanistic claim","pmids":["39472448"],"is_preprint":false},{"year":2022,"finding":"CHRNA5 regulates YAP activity in hepatocellular carcinoma (HCC): both in vitro and in vivo assays showed CHRNA5 modulates HCC proliferation through YAP. CHRNA5 also promotes HCC stemness by upregulating Nanog, Sox2, and OCT4, and enhances metastasis by regulating EMT-associated genes. CHRNA5 knockdown or overexpression modulated sorafenib sensitivity in HCC cells.","method":"In vitro cell proliferation, migration, invasion assays; YAP activity measurement; stemness gene expression analysis; EMT marker analysis; in vivo xenograft; drug sensitivity assay","journal":"Pharmaceutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional assays with loss- and gain-of-function; single lab; mechanistic link to YAP pathway established by functional readout","pmids":["35214008"],"is_preprint":false},{"year":2022,"finding":"CHRNA5 promotes psoriasis-like inflammation: Chrna5 knockout mice showed significantly reduced severity in an imiquimod-induced psoriasis model. Mechanistically, Chrna5 knockout regulated inflammation through the MAPK kinase kinase-1/c-Jun N-terminal kinase–MAPK/NF-κB pathway. Single-cell sequencing revealed that after Chrna5 knockout, the keratinocyte subpopulation was reduced and Jak/STAT signaling was downregulated. Silencing CHRNA5 in human keratinocytes inhibited proliferation and migration.","method":"Chrna5 knockout mice; imiquimod-induced psoriasis model; single-cell RNA sequencing; western blot for MAPK/NF-κB pathway; siRNA knockdown in human keratinocytes; proliferation and migration assays","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo knockout model complemented by single-cell transcriptomics and in vitro knockdown; multiple readouts; single lab","pmids":["35513071"],"is_preprint":false},{"year":2018,"finding":"CHRNA5 siRNA knockdown in MCF7 breast cancer cells reduced cell viability and DNA synthesis, indicating G1 cell cycle arrest, and increased apoptotic sub-G1 population. Mechanistically, CHRNA5 depletion decreased phosphorylated RB (Ser807/811), increased the BAX/BCL2 ratio, and reduced total and phosphorylated CHEK1 (Ser345). Co-exposure to topoisomerase inhibitors with CHRNA5 siRNA enhanced chemosensitivity, potentially due to reduced DNA damage response.","method":"siRNA knockdown; cell viability (CCK-8 equivalent); flow cytometry cell cycle analysis; western blot for RB, BAX, BCL2, CHEK1; gene expression microarray; topoisomerase inhibitor co-treatment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional and molecular readouts following RNAi; correlation with CHEK1 expression validated in external datasets; single lab","pmids":["30543688"],"is_preprint":false},{"year":2023,"finding":"Nicotine downregulates JWA expression via the CHRNA5-mediated AKT pathway in lung cancer cells: CHRNA5 knockdown reduced AKT signaling, leading to lower JWA expression, which in turn enhanced CD44 expression through inhibition of SP1 ubiquitination-mediated degradation, promoting lung cancer cell stemness (colony and spheroid formation) and progression. This pathway was validated in vivo, with JAC4 inhibiting nicotine-triggered tumor progression through the JWA/SP1/CD44 axis.","method":"GSEA; siRNA knockdown; western blot for AKT, p-AKT, SP1, CD44; ubiquitination assay; colony and spheroid formation assays; in vivo tumor xenograft","journal":"Ecotoxicology and environmental safety","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway delineated with multiple functional assays and in vivo validation; single lab, multiple complementary approaches","pmids":["37224781"],"is_preprint":false}],"current_model":"CHRNA5 encodes the α5 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), which assembles into heteromeric receptors (e.g., α4β2α5, α3β4α5) to modulate cholinergic signaling: in the prefrontal cortex, α5-containing receptors mediate rapid-onset cholinergic excitation of corticothalamic layer VI neurons and protect against desensitization; in the interpeduncular nucleus, α5-containing receptors mediate nicotine aversion via GABAergic neurons that project to mesopontine raphe and tegmentum; the common risk variant rs16969968 (D398N) reduces aversive responses to nicotine (demonstrated by IV nicotine challenge in humans and electrophysiology in transgenic rodents), increases nicotine and alcohol self-administration and relapse, and causes rapid desensitization of nicotinic currents in human iPSC-derived neurons; CHRNA5 expression is controlled by promoter haplotypes and cis-regulatory variants that alter mRNA levels through changes in DNA methylation and transcription factor binding (including SP1 and ASCL1 in SCLC); in cancer cells, CHRNA5 acts as a positive regulator of proliferation, migration, invasion, and drug resistance through downstream pathways including MEK/ERK, AKT/JWA/SP1/CD44, YAP, and MAPK/NF-κB signaling, while in normal bronchial cells it acts as a negative regulator of nicotine-induced motility."},"narrative":{"mechanistic_narrative":"CHRNA5 encodes the α5 subunit of neuronal nicotinic acetylcholine receptors, which incorporates into heteromeric receptors to shape cholinergic and nicotine-driven signaling across distinct neural circuits and to modulate proliferative signaling in epithelial and cancer cells [PMID:29954848, PMID:32817066]. In the prefrontal cortex, α5 is essential for the rapid onset of postsynaptic nicotinic excitation in layer VI corticothalamic neurons and protects these responses from desensitization, an effect allosterically restored by the α-α site agonist NS9283 [PMID:32817066]; α5 incorporation into α4β2* receptors in this circuit also determines the direction of developmental nicotine teratogenesis on neuronal morphology and currents [PMID:24055499]. In the interpeduncular nucleus, Chrna5-expressing GABAergic neurons projecting to mesopontine raphe and tegmentum mediate the aversive valence of nicotine [PMID:29954848]. The common coding variant rs16969968 (D398N) is a central functional determinant: it reduces aversive subjective responses to intravenous nicotine in humans [PMID:25948103], increases nicotine and alcohol self-administration and relapse in knock-in rodents with altered IPN reactivity [PMID:30293722, PMID:31288250], and confers increased excitatory responses with rapid desensitization in human iPSC-derived neurons [PMID:27698409]. CHRNA5 expression is governed by 5' promoter haplotypes and cis-regulatory variants acting through SP1 binding, ASCL1 transcription, and DNA methylation, with low-expression haplotypes tracking nicotine-dependence and lung-cancer risk [PMID:20124469, PMID:20733116, PMID:21858091, PMID:26220977]. In cancer, CHRNA5 functions as a positive regulator of proliferation, migration, invasion, and drug resistance through MEK/ERK signaling and a physical interaction with CES1 in head and neck carcinoma [PMID:39472448], YAP-dependent proliferation and stemness in hepatocellular carcinoma [PMID:35214008], and an AKT/JWA/SP1/CD44 axis in lung cancer [PMID:37224781], whereas in non-transformed bronchial cells it acts as a negative regulator of nicotine-induced motility [PMID:21586512].","teleology":[{"year":2001,"claim":"Establishing the genomic architecture of CHRNA5 was the prerequisite for any regulatory or variant analysis, defining its exon-intron structure and its tail-to-tail 3'-UTR overlap with CHRNA3 within the clustered locus.","evidence":"Genomic sequencing and exon-intron structure analysis with polymorphism identification across the CHRNA5/A3/B4 cluster","pmids":["11721883"],"confidence":"Medium","gaps":["Did not assign function to the identified polymorphisms","No expression or receptor-assembly data"]},{"year":2010,"claim":"Two studies addressed how CHRNA5 transcription is controlled, showing the clustered subunit genes are coordinately driven by ASCL1 in SCLC and that 5' promoter haplotypes set CHRNA5 mRNA levels in lung tissue.","evidence":"siRNA knockdown of ASCL1 with qRT-PCR in lung cancer lines; qRT-PCR on human lung tissue plus luciferase reporter assays across four lung cancer cell lines","pmids":["20124469","20733116"],"confidence":"High","gaps":["ASCL1 knockdown effect shown for CHRNA3/B4, not direct CHRNA5 transcription","Did not identify the specific causal promoter nucleotides","No link to receptor function"]},{"year":2011,"claim":"Reporter-based dissection of promoter variants identified loss of an SP1 site and a distal repressor element as cis-regulatory mechanisms, mapping how risk alleles lower CHRNA5 expression.","evidence":"Luciferase reporter assays in neuroblastoma cells with allelic expression imbalance analysis in post-mortem brain","pmids":["21858091"],"confidence":"Medium","gaps":["SP1 binding inferred from sequence, not directly demonstrated","Reporter assays in heterologous cells may not reflect endogenous chromatin"]},{"year":2011,"claim":"Functional studies in epithelial cells revealed an unexpected role for CHRNA5 as a brake on nicotine-induced motility, distinguishing its behavior in normal bronchial cells from its later pro-tumorigenic roles.","evidence":"siRNA knockdown and α-conotoxin MII inhibition with motility, invasion, and calcium influx assays in bronchial and lung cancer cells","pmids":["21586512"],"confidence":"Medium","gaps":["Mechanism linking α5 loss to CHRNA7-dependent motility unresolved","Single lab; effects on adhesion molecules correlative"]},{"year":2011,"claim":"Gain-of-function overexpression of the human gene cluster in mice established that altered subunit dosage changes nicotine sensitivity, habenular/VTA circuit activation, and self-administration.","evidence":"BAC transgenic overexpression with radioligand binding, c-Fos imaging, and nicotine self-administration","pmids":["22101982"],"confidence":"High","gaps":["Cluster overexpression cannot isolate CHRNA5-specific contribution","Did not test the rs16969968 variant"]},{"year":2013,"claim":"Quantitative allele-specific expression in human brain demonstrated that cis-regulatory variants act directly on CHRNA5 transcript levels in the cortex, extending the regulatory mechanism from lung/cancer cells to relevant neural tissue.","evidence":"Allele-specific gene expression in post-mortem frontal cortex from two ancestral populations","pmids":["24303001"],"confidence":"Medium","gaps":["10 correlated variants could not be resolved to a single causal site","No functional receptor readout"]},{"year":2013,"claim":"A genetic-knockout developmental study showed that α5 incorporation into prefrontal α4β2* receptors dictates the direction of nicotine teratogenesis, providing a circuit-level mechanism for α5-dependent vulnerability.","evidence":"Developmental nicotine exposure in wildtype and Chrna5 knockout mice with patch-clamp electrophysiology and morphometry of layer VI neurons","pmids":["24055499"],"confidence":"High","gaps":["Molecular basis of the morphological reversal in knockouts not defined","Single lab"]},{"year":2015,"claim":"Two studies tied the rs16969968 risk allele and a methylation-controlling SNP to human phenotype, showing the N398 allele blunts nicotine aversion and that lower CHRNA5 methylation/expression increases dependence risk.","evidence":"Intravenous nicotine challenge in humans of two ancestries; cis-meQTL across four brain regions and haplotype association in five cohorts (N=11,096)","pmids":["25948103","26220977"],"confidence":"High","gaps":["Receptor-level mechanism of blunted aversion not addressed in the human challenge study","Causal direction between methylation and expression inferred from association"]},{"year":2016,"claim":"Human iPSC-derived neurons provided a cell-autonomous readout, showing the N398 allele increases nicotine-evoked excitatory currents but accelerates desensitization, connecting genotype to receptor biophysics in human cells.","evidence":"Whole-cell electrophysiology in iPSC-derived dopaminergic and glutamatergic neurons from D398 versus N398 donors","pmids":["27698409"],"confidence":"High","gaps":["Donor lines not isogenic","Single lab; receptor subunit composition not directly resolved"]},{"year":2018,"claim":"Circuit-resolving studies localized α5 function to GABAergic IPN neurons mediating nicotine aversion and showed the human risk variant alters IPN reactivity and increases nicotine self-administration and relapse in knock-in rats.","evidence":"Chrna5-null electrophysiology, Chrna5Cre BAC transgenics, optogenetics and circuit tracing in mice; zinc-finger-nuclease knock-in rats with self-administration, reinstatement, and IPN electrophysiology","pmids":["29954848","30293722"],"confidence":"High","gaps":["Downstream targets of the IPN-to-raphe/tegmentum projection not mapped","Priming requirement for aversion mechanistically unexplained"]},{"year":2018,"claim":"A gene-environment knock-in study showed D398N interacts with developmental nicotine exposure to set later nicotine intake and striatal dopamine release, demonstrating allele-dependent reprogramming.","evidence":"Two-bottle choice consumption and striatal synaptosome dopamine-release assays in D398N knock-in mice with developmental exposure","pmids":["29573323"],"confidence":"Medium","gaps":["Molecular mediator of the divergent dopamine response unknown","Single lab"]},{"year":2019,"claim":"Subsequent work refined the cortical role, identifying Chrna5+ acetylcholine super-responder neurons of subplate identity defined by lynx prototoxin gene expression, and extended the variant's behavioral reach to alcohol and food relapse.","evidence":"Chrna5Cre opto-physiology with single-cell RNA-seq and pharmacology; α5SNP knock-in rats with alcohol/food reinstatement and c-Fos imaging","pmids":["36798433","31288250"],"confidence":"High","gaps":["Functional necessity of lynx prototoxins for α5 regulation not directly tested","Insula c-Fos correlation does not establish causality"]},{"year":2020,"claim":"Optogenetic interrogation defined the kinetic role of α5 in prefrontal layer VI: it confers rapid-onset nicotinic excitation and desensitization resistance, with pharmacological rescue pinpointing the α-α binding site.","evidence":"Optogenetics plus ex vivo electrophysiology in two independent Chrna5 knockout transgenic lines with NS9283 rescue","pmids":["32817066"],"confidence":"High","gaps":["In vivo behavioral consequence of altered kinetics not tested","Receptor stoichiometry underlying the kinetic effect inferred pharmacologically"]},{"year":2024,"claim":"A series of cancer studies established CHRNA5 as a nicotine-activated positive regulator of tumor cell proliferation, invasion, stemness, and drug resistance through distinct downstream pathways across tumor types and an inflammatory tissue.","evidence":"RNAi/overexpression with proliferation, migration, cell-cycle and xenograft assays plus co-IP/docking (HNSC, CES1/MEK-ERK; HCC, YAP; lung, AKT/JWA/SP1/CD44; breast, RB/CHEK1) and Chrna5 knockout in an imiquimod psoriasis model","pmids":["39472448","35214008","37224781","30543688","35513071"],"confidence":"Medium","gaps":["Whether tumor effects require canonical ion-channel activity of α5 is unresolved","CES1 co-IP not reciprocally validated; pathways delineated largely in single labs","Reconciliation with the negative-regulator role in bronchial cells unaddressed"]},{"year":null,"claim":"How the receptor-level kinetic and desensitization phenotypes conferred by α5 and the D398N variant translate into the specific behavioral and circuit-level changes, and how the same subunit acts as a motility brake in normal epithelium yet a pro-tumorigenic signaling node in cancer, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying mechanism linking ion-channel function to the cancer signaling pathways","Stoichiometry and partner-subunit dependence of α5 across tissues not systematically resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[6,10,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,9,17]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[6,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[17,18,21]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,5]}],"complexes":["α4β2α5 nicotinic acetylcholine receptor","α3β4α5 nicotinic acetylcholine receptor"],"partners":["CES1","CHRNA3","CHRNB4","CHRNA4","CHRNB2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P30532","full_name":"Neuronal acetylcholine receptor subunit alpha-5","aliases":[],"length_aa":468,"mass_kda":53.1,"function":"Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators (PubMed:20881005, PubMed:8663494). Has an accessory rather than functional role and is only able to form functional nAChRs when co-assembled with another beta subunit (PubMed:20881005, PubMed:8663494). Participates in pentameric assemblies along with CHRNA3, CHRNA4, CHRNB2 and CHRNB4 (PubMed:20881005, PubMed:8663494). Increases receptor sensitivity to acetylcholine and nicotine when associated with CHRNA4 and CHRNB2 (PubMed:8663494). Plays a role in nicotine addiction (PubMed:20881005)","subcellular_location":"Synaptic cell membrane; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P30532/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CHRNA5","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/CHRNA5","total_profiled":1310},"omim":[{"mim_id":"612052","title":"SMOKING AS A QUANTITATIVE TRAIT LOCUS 3; SQTL3","url":"https://www.omim.org/entry/612052"},{"mim_id":"603204","title":"EPILEPSY, NOCTURNAL FRONTAL LOBE, 2; ENFL2","url":"https://www.omim.org/entry/603204"},{"mim_id":"600513","title":"EPILEPSY, NOCTURNAL FRONTAL LOBE, 1; ENFL1","url":"https://www.omim.org/entry/600513"},{"mim_id":"211980","title":"LUNG CANCER","url":"https://www.omim.org/entry/211980"},{"mim_id":"188890","title":"TOBACCO ADDICTION, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/188890"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Focal adhesion sites","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CHRNA5"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P30532","domains":[{"cath_id":"2.70.170.10","chopping":"43-249","consensus_level":"high","plddt":92.1377,"start":43,"end":249},{"cath_id":"1.20.58.390","chopping":"253-367_404-459","consensus_level":"high","plddt":84.588,"start":253,"end":459}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P30532","model_url":"https://alphafold.ebi.ac.uk/files/AF-P30532-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P30532-F1-predicted_aligned_error_v6.png","plddt_mean":81.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CHRNA5","jax_strain_url":"https://www.jax.org/strain/search?query=CHRNA5"},"sequence":{"accession":"P30532","fasta_url":"https://rest.uniprot.org/uniprotkb/P30532.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P30532/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P30532"}},"corpus_meta":[{"pmid":"19706762","id":"PMC_19706762","title":"The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19706762","citation_count":218,"is_preprint":false},{"pmid":"18618000","id":"PMC_18618000","title":"A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction.","date":"2008","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18618000","citation_count":216,"is_preprint":false},{"pmid":"18957677","id":"PMC_18957677","title":"The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer.","date":"2008","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/18957677","citation_count":184,"is_preprint":false},{"pmid":"18414406","id":"PMC_18414406","title":"Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence.","date":"2008","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18414406","citation_count":180,"is_preprint":false},{"pmid":"21747048","id":"PMC_21747048","title":"Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.","date":"2011","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/21747048","citation_count":152,"is_preprint":false},{"pmid":"18163978","id":"PMC_18163978","title":"The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults.","date":"2007","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18163978","citation_count":146,"is_preprint":false},{"pmid":"19429911","id":"PMC_19429911","title":"A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19429911","citation_count":121,"is_preprint":false},{"pmid":"18783506","id":"PMC_18783506","title":"Association of a single nucleotide polymorphism in neuronal acetylcholine receptor subunit alpha 5 (CHRNA5) with smoking status and with 'pleasurable buzz' during early experimentation with smoking.","date":"2008","source":"Addiction (Abingdon, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18783506","citation_count":118,"is_preprint":false},{"pmid":"18519132","id":"PMC_18519132","title":"A risk allele for nicotine dependence in CHRNA5 is a protective allele for cocaine dependence.","date":"2008","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18519132","citation_count":117,"is_preprint":false},{"pmid":"22648373","id":"PMC_22648373","title":"Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.","date":"2012","source":"The American journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22648373","citation_count":115,"is_preprint":false},{"pmid":"22071378","id":"PMC_22071378","title":"Association of the CHRNA5-A3-B4 gene cluster with heaviness of smoking: a meta-analysis.","date":"2011","source":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","url":"https://pubmed.ncbi.nlm.nih.gov/22071378","citation_count":94,"is_preprint":false},{"pmid":"21593077","id":"PMC_21593077","title":"Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking status to influence body mass index.","date":"2011","source":"International journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/21593077","citation_count":94,"is_preprint":false},{"pmid":"19628476","id":"PMC_19628476","title":"Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19628476","citation_count":91,"is_preprint":false},{"pmid":"22536069","id":"PMC_22536069","title":"Higher FKBP5, COMT, CHRNA5, and CRHR1 allele burdens are associated with PTSD and interact with trauma exposure: implications for neuropsychiatric research and treatment.","date":"2012","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/22536069","citation_count":79,"is_preprint":false},{"pmid":"21268243","id":"PMC_21268243","title":"Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.","date":"2011","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21268243","citation_count":74,"is_preprint":false},{"pmid":"20685379","id":"PMC_20685379","title":"The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer.","date":"2010","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/20685379","citation_count":70,"is_preprint":false},{"pmid":"21968931","id":"PMC_21968931","title":"The CHRNA5-A3-B4 gene cluster in nicotine addiction.","date":"2011","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21968931","citation_count":70,"is_preprint":false},{"pmid":"20808433","id":"PMC_20808433","title":"Associations of variants in CHRNA5/A3/B4 gene cluster with smoking behaviors in a Korean population.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20808433","citation_count":70,"is_preprint":false},{"pmid":"25948103","id":"PMC_25948103","title":"A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans.","date":"2015","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25948103","citation_count":67,"is_preprint":false},{"pmid":"20564069","id":"PMC_20564069","title":"Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk.","date":"2010","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20564069","citation_count":63,"is_preprint":false},{"pmid":"27871728","id":"PMC_27871728","title":"The CHRNA5-A3-B4 Gene Cluster and Smoking: From Discovery to Therapeutics.","date":"2016","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/27871728","citation_count":62,"is_preprint":false},{"pmid":"25873736","id":"PMC_25873736","title":"CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis.","date":"2015","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/25873736","citation_count":62,"is_preprint":false},{"pmid":"21168125","id":"PMC_21168125","title":"TTC12-ANKK1-DRD2 and CHRNA5-CHRNA3-CHRNB4 influence different pathways leading to smoking behavior from adolescence to mid-adulthood.","date":"2010","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21168125","citation_count":62,"is_preprint":false},{"pmid":"22956269","id":"PMC_22956269","title":"Genetic variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) interacts with maternal self-reported smoking status during pregnancy to influence birth weight.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22956269","citation_count":59,"is_preprint":false},{"pmid":"21418140","id":"PMC_21418140","title":"A CHRNA5 allele related to nicotine addiction and schizophrenia.","date":"2011","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/21418140","citation_count":55,"is_preprint":false},{"pmid":"22544838","id":"PMC_22544838","title":"From men to mice: CHRNA5/CHRNA3, smoking behavior and disease.","date":"2012","source":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","url":"https://pubmed.ncbi.nlm.nih.gov/22544838","citation_count":54,"is_preprint":false},{"pmid":"20886544","id":"PMC_20886544","title":"Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNB4 cluster are associated with cognitive performance.","date":"2010","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20886544","citation_count":52,"is_preprint":false},{"pmid":"19859904","id":"PMC_19859904","title":"Association and interaction analysis of variants in CHRNA5/CHRNA3/CHRNB4 gene cluster with nicotine dependence in African and European Americans.","date":"2010","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19859904","citation_count":51,"is_preprint":false},{"pmid":"22241830","id":"PMC_22241830","title":"Analysis of detailed phenotype profiles reveals CHRNA5-CHRNA3-CHRNB4 gene cluster association with several nicotine dependence traits.","date":"2012","source":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","url":"https://pubmed.ncbi.nlm.nih.gov/22241830","citation_count":50,"is_preprint":false},{"pmid":"25474695","id":"PMC_25474695","title":"Stratification by smoking status reveals an association of CHRNA5-A3-B4 genotype with body mass index in never smokers.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25474695","citation_count":49,"is_preprint":false},{"pmid":"25471942","id":"PMC_25471942","title":"Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism.","date":"2014","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25471942","citation_count":47,"is_preprint":false},{"pmid":"20581870","id":"PMC_20581870","title":"From smoking to lung cancer: the CHRNA5/A3/B4 connection.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20581870","citation_count":45,"is_preprint":false},{"pmid":"21586512","id":"PMC_21586512","title":"CHRNA5 as negative regulator of nicotine signaling in normal and cancer bronchial cells: effects on motility, migration and p63 expression.","date":"2011","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21586512","citation_count":43,"is_preprint":false},{"pmid":"21764527","id":"PMC_21764527","title":"Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women.","date":"2011","source":"Drug and alcohol dependence","url":"https://pubmed.ncbi.nlm.nih.gov/21764527","citation_count":41,"is_preprint":false},{"pmid":"30366711","id":"PMC_30366711","title":"Relationship of common variants in CHRNA5 with early-onset schizophrenia and executive function.","date":"2018","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/30366711","citation_count":40,"is_preprint":false},{"pmid":"29954848","id":"PMC_29954848","title":"Chrna5-Expressing Neurons in the Interpeduncular Nucleus Mediate Aversion Primed by Prior Stimulation or Nicotine Exposure.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29954848","citation_count":38,"is_preprint":false},{"pmid":"20733116","id":"PMC_20733116","title":"Promoter polymorphisms and transcript levels of nicotinic receptor CHRNA5.","date":"2010","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/20733116","citation_count":36,"is_preprint":false},{"pmid":"30293722","id":"PMC_30293722","title":"A Human Polymorphism in CHRNA5 Is Linked to Relapse to Nicotine Seeking in Transgenic Rats.","date":"2018","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/30293722","citation_count":36,"is_preprint":false},{"pmid":"27543155","id":"PMC_27543155","title":"Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis.","date":"2016","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/27543155","citation_count":35,"is_preprint":false},{"pmid":"26010901","id":"PMC_26010901","title":"Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26010901","citation_count":34,"is_preprint":false},{"pmid":"26239294","id":"PMC_26239294","title":"Rare, low frequency and common coding variants in CHRNA5 and their contribution to nicotine dependence in European and African Americans.","date":"2015","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26239294","citation_count":31,"is_preprint":false},{"pmid":"27698409","id":"PMC_27698409","title":"Increased nicotine response in iPSC-derived human neurons carrying the CHRNA5 N398 allele.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27698409","citation_count":31,"is_preprint":false},{"pmid":"26142345","id":"PMC_26142345","title":"Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.","date":"2015","source":"Drug and alcohol dependence","url":"https://pubmed.ncbi.nlm.nih.gov/26142345","citation_count":30,"is_preprint":false},{"pmid":"24186853","id":"PMC_24186853","title":"Distinct loci in the CHRNA5/CHRNA3/CHRNB4 gene cluster are associated with onset of regular smoking.","date":"2013","source":"Genetic epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/24186853","citation_count":29,"is_preprint":false},{"pmid":"22101982","id":"PMC_22101982","title":"Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects.","date":"2011","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/22101982","citation_count":29,"is_preprint":false},{"pmid":"20124469","id":"PMC_20124469","title":"ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus.","date":"2010","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/20124469","citation_count":28,"is_preprint":false},{"pmid":"31072760","id":"PMC_31072760","title":"Low Smoking Exposure, the Adolescent Brain, and the Modulating Role of CHRNA5 Polymorphisms.","date":"2019","source":"Biological psychiatry. Cognitive neuroscience and neuroimaging","url":"https://pubmed.ncbi.nlm.nih.gov/31072760","citation_count":26,"is_preprint":false},{"pmid":"21559498","id":"PMC_21559498","title":"Chromosome 15q25 (CHRNA3-CHRNA5) variation impacts indirectly on lung cancer risk.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21559498","citation_count":25,"is_preprint":false},{"pmid":"11721883","id":"PMC_11721883","title":"Characterization of the genomic structure of the human neuronal nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster and identification of novel intragenic polymorphisms.","date":"2001","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11721883","citation_count":25,"is_preprint":false},{"pmid":"26220977","id":"PMC_26220977","title":"A multiancestry study identifies novel genetic associations with CHRNA5 methylation in human brain and risk of nicotine dependence.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26220977","citation_count":25,"is_preprint":false},{"pmid":"20631687","id":"PMC_20631687","title":"Variation in the nicotinic acetylcholine receptor gene cluster CHRNA5-CHRNA3-CHRNB4 and its interaction with recent tobacco use influence cognitive flexibility.","date":"2010","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20631687","citation_count":25,"is_preprint":false},{"pmid":"27758088","id":"PMC_27758088","title":"The CHRNA5/CHRNA3/CHRNB4 Nicotinic Receptor Regulome: Genomic Architecture, Regulatory Variants, and Clinical Associations.","date":"2016","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/27758088","citation_count":24,"is_preprint":false},{"pmid":"26689306","id":"PMC_26689306","title":"Gene variance in the nicotinic receptor cluster (CHRNA5-CHRNA3-CHRNB4) predicts death from cardiopulmonary disease and cancer in smokers.","date":"2015","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26689306","citation_count":24,"is_preprint":false},{"pmid":"30202994","id":"PMC_30202994","title":"Genome-Wide Variants Shared Between Smoking Quantity and Schizophrenia on 15q25 Are Associated With CHRNA5 Expression in the Brain.","date":"2019","source":"Schizophrenia bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/30202994","citation_count":24,"is_preprint":false},{"pmid":"24819610","id":"PMC_24819610","title":"DRD2/CHRNA5 interaction on prefrontal biology and physiology during working memory.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24819610","citation_count":23,"is_preprint":false},{"pmid":"24055499","id":"PMC_24055499","title":"Chrna5 genotype determines the long-lasting effects of developmental in vivo nicotine exposure on prefrontal attention circuitry.","date":"2013","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24055499","citation_count":23,"is_preprint":false},{"pmid":"32602170","id":"PMC_32602170","title":"Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial.","date":"2020","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32602170","citation_count":22,"is_preprint":false},{"pmid":"22042234","id":"PMC_22042234","title":"Externalizing behaviors are associated with SNPs in the CHRNA5/CHRNA3/CHRNB4 gene cluster.","date":"2011","source":"Behavior genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22042234","citation_count":22,"is_preprint":false},{"pmid":"23875064","id":"PMC_23875064","title":"Scrutiny of the CHRNA5-CHRNA3-CHRNB4 smoking behavior locus reveals a novel association with alcohol use in a Finnish population based study.","date":"2013","source":"International journal of molecular epidemiology and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23875064","citation_count":22,"is_preprint":false},{"pmid":"39472448","id":"PMC_39472448","title":"Nicotine-induced CHRNA5 activation modulates CES1 expression, impacting head and neck squamous cell carcinoma recurrence and metastasis via MEK/ERK pathway.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39472448","citation_count":21,"is_preprint":false},{"pmid":"31288250","id":"PMC_31288250","title":"Profound alteration in reward processing due to a human polymorphism in CHRNA5: a role in alcohol dependence and feeding behavior.","date":"2019","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31288250","citation_count":21,"is_preprint":false},{"pmid":"22382757","id":"PMC_22382757","title":"The CHRNA5/A3/B4 gene cluster and tobacco, alcohol, cannabis, inhalants and other substance use initiation: replication and new findings using mixture analyses.","date":"2012","source":"Behavior genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22382757","citation_count":21,"is_preprint":false},{"pmid":"32738310","id":"PMC_32738310","title":"Genetic susceptibility to nicotine addiction: Advances and shortcomings in our understanding of the CHRNA5/A3/B4 gene cluster contribution.","date":"2020","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32738310","citation_count":20,"is_preprint":false},{"pmid":"23077662","id":"PMC_23077662","title":"Method for evaluating multiple mediators: mediating effects of smoking and COPD on the association between the CHRNA5-A3 variant and lung cancer risk.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23077662","citation_count":20,"is_preprint":false},{"pmid":"21858091","id":"PMC_21858091","title":"In vitro and ex vivo analysis of CHRNA3 and CHRNA5 haplotype expression.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21858091","citation_count":19,"is_preprint":false},{"pmid":"22884254","id":"PMC_22884254","title":"Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: gene and smoking status interaction.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22884254","citation_count":19,"is_preprint":false},{"pmid":"32817066","id":"PMC_32817066","title":"Chrna5 is Essential for a Rapid and Protected Response to Optogenetic Release of Endogenous Acetylcholine in Prefrontal Cortex.","date":"2020","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32817066","citation_count":19,"is_preprint":false},{"pmid":"21810735","id":"PMC_21810735","title":"Single nucleotide polymorphisms in CHRNA5 rs16969968, CHRNA3 rs578776, and LOC123688 rs8034191 are associated with heaviness of smoking in women in Northeastern Ontario, Canada.","date":"2011","source":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","url":"https://pubmed.ncbi.nlm.nih.gov/21810735","citation_count":19,"is_preprint":false},{"pmid":"21385908","id":"PMC_21385908","title":"Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers.","date":"2011","source":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","url":"https://pubmed.ncbi.nlm.nih.gov/21385908","citation_count":19,"is_preprint":false},{"pmid":"24303001","id":"PMC_24303001","title":"Cis-regulatory variants affect CHRNA5 mRNA expression in populations of African and European ancestry.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24303001","citation_count":18,"is_preprint":false},{"pmid":"23397474","id":"PMC_23397474","title":"Polymorphisms of CHRNA5-CHRNA3-CHRNB4 Gene Cluster and NSCLC Risk in Chinese Population.","date":"2012","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23397474","citation_count":17,"is_preprint":false},{"pmid":"21748402","id":"PMC_21748402","title":"A twin association study of nicotine dependence with markers in the CHRNA3 and CHRNA5 genes.","date":"2011","source":"Behavior genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21748402","citation_count":17,"is_preprint":false},{"pmid":"36798433","id":"PMC_36798433","title":"Chrna5 and lynx prototoxins identify acetylcholine super-responder subplate neurons.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36798433","citation_count":16,"is_preprint":false},{"pmid":"35214008","id":"PMC_35214008","title":"CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity.","date":"2022","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/35214008","citation_count":16,"is_preprint":false},{"pmid":"25073833","id":"PMC_25073833","title":"Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction.","date":"2014","source":"Drug and alcohol dependence","url":"https://pubmed.ncbi.nlm.nih.gov/25073833","citation_count":16,"is_preprint":false},{"pmid":"27355804","id":"PMC_27355804","title":"SNPs in NRXN1 and CHRNA5 are associated to smoking and regulation of GABAergic and glutamatergic pathways.","date":"2016","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/27355804","citation_count":15,"is_preprint":false},{"pmid":"26693074","id":"PMC_26693074","title":"CHRNA5 polymorphisms and risk of lung cancer in Chinese Han smokers.","date":"2015","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26693074","citation_count":15,"is_preprint":false},{"pmid":"23692359","id":"PMC_23692359","title":"CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users.","date":"2013","source":"Addiction (Abingdon, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23692359","citation_count":15,"is_preprint":false},{"pmid":"25214750","id":"PMC_25214750","title":"Genomics and personalized medicine: CHRNA5-CHRNA3-CHRNB4 and smoking cessation treatment.","date":"2013","source":"Journal of food and drug analysis","url":"https://pubmed.ncbi.nlm.nih.gov/25214750","citation_count":14,"is_preprint":false},{"pmid":"37224781","id":"PMC_37224781","title":"JWA inhibits nicotine-induced lung cancer stemness and progression through CHRNA5/AKT-mediated JWA/SP1/CD44 axis.","date":"2023","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/37224781","citation_count":14,"is_preprint":false},{"pmid":"30543688","id":"PMC_30543688","title":"Cholinergic Receptor Nicotinic Alpha 5 (CHRNA5) RNAi is associated with cell cycle inhibition, apoptosis, DNA damage response and drug sensitivity in breast cancer.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30543688","citation_count":14,"is_preprint":false},{"pmid":"24727484","id":"PMC_24727484","title":"CHRNA5 variant predicts smoking cessation in patients with acute myocardial infarction.","date":"2014","source":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","url":"https://pubmed.ncbi.nlm.nih.gov/24727484","citation_count":14,"is_preprint":false},{"pmid":"20438829","id":"PMC_20438829","title":"Low ethanol concentration alters CHRNA5 RNA levels during early human development.","date":"2010","source":"Reproductive toxicology (Elmsford, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20438829","citation_count":14,"is_preprint":false},{"pmid":"23458267","id":"PMC_23458267","title":"Examination of rare missense variants in the CHRNA5-A3-B4 gene cluster to level of response to alcohol in the San Diego Sibling Pair study.","date":"2013","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/23458267","citation_count":14,"is_preprint":false},{"pmid":"30453884","id":"PMC_30453884","title":"Combined genetic influence of the nicotinic receptor gene cluster CHRNA5/A3/B4 on nicotine dependence.","date":"2018","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/30453884","citation_count":13,"is_preprint":false},{"pmid":"23844051","id":"PMC_23844051","title":"Association of CHRNA5-A3-B4 variation with esophageal squamous cell carcinoma risk and smoking behaviors in a Chinese population.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23844051","citation_count":13,"is_preprint":false},{"pmid":"21248747","id":"PMC_21248747","title":"Association of a variant in the CHRNA5-A3-B4 gene cluster region to heavy smoking in the Italian population.","date":"2011","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/21248747","citation_count":13,"is_preprint":false},{"pmid":"35513071","id":"PMC_35513071","title":"CHRNA5 Is Overexpressed in Patients with Psoriasis and Promotes Psoriasis-Like Inflammation in Mouse Models.","date":"2022","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35513071","citation_count":11,"is_preprint":false},{"pmid":"32152934","id":"PMC_32152934","title":"Association of CHRNA5 Gene Variants with Crack Cocaine Addiction.","date":"2020","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32152934","citation_count":11,"is_preprint":false},{"pmid":"23011884","id":"PMC_23011884","title":"Functional effect of polymorphisms in 15q25 locus on CHRNA5 mRNA, bulky DNA adducts and TP53 mutations.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23011884","citation_count":11,"is_preprint":false},{"pmid":"24588897","id":"PMC_24588897","title":"CHRNA5 and CHRNA3 variants and level of neuroticism in young adult Mexican American men and women.","date":"2014","source":"Twin research and human genetics : the official journal of the International Society for Twin Studies","url":"https://pubmed.ncbi.nlm.nih.gov/24588897","citation_count":11,"is_preprint":false},{"pmid":"22336398","id":"PMC_22336398","title":"Nicotine dependence and comorbid psychiatric disorders: examination of specific genetic variants in the CHRNA5-A3-B4 nicotinic receptor genes.","date":"2012","source":"Drug and alcohol dependence","url":"https://pubmed.ncbi.nlm.nih.gov/22336398","citation_count":11,"is_preprint":false},{"pmid":"29573323","id":"PMC_29573323","title":"The interaction of the Chrna5 D398N variant with developmental nicotine exposure.","date":"2018","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/29573323","citation_count":11,"is_preprint":false},{"pmid":"23729684","id":"PMC_23729684","title":"Smoking status, snus use, and variation at the CHRNA5-CHRNA3-CHRNB4 locus in relation to obesity: the GLACIER study.","date":"2013","source":"American journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/23729684","citation_count":11,"is_preprint":false},{"pmid":"24451018","id":"PMC_24451018","title":"A recall-by-genotype study of CHRNA5-A3-B4 genotype, cotinine and smoking topography: study protocol.","date":"2014","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24451018","citation_count":11,"is_preprint":false},{"pmid":"24682045","id":"PMC_24682045","title":"Identification of CHRNA5 rare variants in African-American heavy smokers.","date":"2014","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24682045","citation_count":10,"is_preprint":false},{"pmid":"34707353","id":"PMC_34707353","title":"The Cumulative Effect of Gene-Gene Interactions Between GSTM1, CHRNA3, CHRNA5 and SOD3 Gene Polymorphisms Combined with Smoking on COPD Risk.","date":"2021","source":"International journal of chronic obstructive pulmonary disease","url":"https://pubmed.ncbi.nlm.nih.gov/34707353","citation_count":10,"is_preprint":false},{"pmid":"21955800","id":"PMC_21955800","title":"The polymorphism of the CHRNA5 gene and the strength of nicotine addiction in lung cancer and COPD patients.","date":"2012","source":"European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)","url":"https://pubmed.ncbi.nlm.nih.gov/21955800","citation_count":10,"is_preprint":false},{"pmid":"29416783","id":"PMC_29416783","title":"Study on polymorphisms in CHRNA5/CHRNA3/CHRNB4 gene cluster and the associated with the risk of non-small cell lung cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29416783","citation_count":10,"is_preprint":false},{"pmid":"28474623","id":"PMC_28474623","title":"IREB2, CHRNA5, CHRNA3, FAM13A & hedgehog interacting protein genes polymorphisms & risk of chronic obstructive pulmonary disease in Tatar population from Russia.","date":"2016","source":"The Indian journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/28474623","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55235,"output_tokens":6687,"usd":0.133005,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15969,"output_tokens":4915,"usd":0.10136,"stage2_stop_reason":"end_turn"},"total_usd":0.234365,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"CHRNA5 acts as a negative regulator of nicotine signaling in bronchial cells: siRNA-mediated silencing of CHRNA5, or pharmacological inhibition with α-conotoxin MII, increased cell motility, invasiveness, and calcium influx in both non-transformed bronchial cells and lung cancer cell lines, mimicking the effect of nicotine. These effects were blocked by inhibiting CHRNA7 (α7 nAChR). Silencing CHRNA5 also decreased expression of cell adhesion molecules P120 and ZO-1 in lung cancer cells and reduced DeltaNp63α expression in squamous cell carcinoma lines.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition (α-conotoxin MII), in vitro motility/invasion assays, calcium influx measurement, western blot for adhesion molecules\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RNAi, pharmacological antagonism, functional assays) in a single lab; consistent results across cell types\",\n      \"pmids\": [\"21586512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ASCL1 transcription factor regulates expression of the CHRNA5/A3/B4 gene cluster in small-cell lung carcinoma (SCLC): knockdown of ASCL1 in SCLC cells significantly decreased expression of the α3 and β4 nAChR subunit genes without affecting other highly expressed nAChR genes, and without effect in non-SCLC lines. The clustered nAChR genes (CHRNA5, CHRNA3, CHRNB4) are coordinately overexpressed in SCLC and contain putative ASCL1 binding sites in their promoters.\",\n      \"method\": \"Quantitative RT-PCR in lung cancer cell lines and patient samples; siRNA knockdown of ASCL1; in silico promoter analysis\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct loss-of-function knockdown with specific gene-expression readout in multiple cell lines; single lab, two complementary methods\",\n      \"pmids\": [\"20124469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Promoter haplotypes of CHRNA5 significantly regulate its mRNA transcript levels in human lung tissue. The delTTC promoter haplotype was associated with the highest CHRNA5 transcript levels, while the insTGG haplotype (linked to risk alleles for nicotine dependence, lung cancer, and COPD) was associated with the lowest transcript levels. Luciferase reporter assays in human lung cancer cell lines confirmed that 5' promoter haplotypes significantly altered CHRNA5 promoter activity, while 3'-UTR variants did not.\",\n      \"method\": \"Quantitative RT-PCR on human lung tissue from 68 patients; luciferase reporter assays in four human lung cancer cell lines (A549, H460, H520, H596)\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional reporter assay plus ex vivo mRNA quantification in human tissue, replicated across multiple cell lines; two independent orthogonal methods in one study\",\n      \"pmids\": [\"20733116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CHRNA5 promoter variants affect allelic expression: luciferase reporter assays showed that deletion at rs3841324 combined with variation at rs503464 decreased CHRNA5 promoter-derived activity, potentially by loss of an SP-1 binding site. Variations within the CHRNA5 5'UTR (rs55853698 and rs55781567) also altered luciferase expression. A distal promoter region was found to strongly repress CHRNA5 transcription.\",\n      \"method\": \"Luciferase reporter assays in BE(2)-C neuroblastoma cells; allelic expression imbalance (AEI) analysis in post-mortem brain tissue; heterologous promoter constructs\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional reporter assay with mutagenesis-like variant analysis plus ex vivo AEI; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21858091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cis-regulatory variants in the CHRNA5-CHRNA3-CHRNB4 region exert a direct cis-regulatory effect on CHRNA5 transcript levels in human frontal cortex. Quantitative allele-specific expression analysis in African-American (n=49) and European-American (n=111) brain samples identified 10 highly correlated variants in a 9 kb region as potential functional variants modifying CHRNA5 mRNA expression levels.\",\n      \"method\": \"Quantitative allele-specific gene expression (ASE) in post-mortem human frontal cortex from subjects of African and European ancestry\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cis-regulatory measurement in human brain tissue using ASE, two ancestral populations as internal replication; single lab\",\n      \"pmids\": [\"24303001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The intronic CHRNB4 SNP rs11636753 is associated with CHRNA5 DNA methylation levels in multiple human brain regions (prefrontal cortex, frontal cortex, temporal cortex, pons). The rs11636753 major (G) allele was associated with lower CHRNA5 DNA methylation, lower CHRNA5 mRNA expression, and increased nicotine dependence risk. Haplotype analysis showed rs11636753-G and rs16969968-A alleles together increased nicotine dependence risk more than either alone, connecting methylation differences to mRNA expression and dependence risk.\",\n      \"method\": \"cis-meQTL analysis using SNP genotypes and DNA methylation in post-mortem brain (BrainCloud and Brain QTL cohorts, N=240); expression analysis; haplotype association in five independent cohorts (N=11,096)\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — meQTL replicated across four brain regions and five independent cohorts; multiple orthogonal methods (methylation, mRNA, dependence phenotype) connecting mechanism to phenotype\",\n      \"pmids\": [\"26220977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In the mouse interpeduncular nucleus (IPN), α5-null (Chrna5 knockout) mice show markedly reduced electrophysiological responses to nicotinic acetylcholine receptor stimulation. Chrna5-expressing IPN neurons are GABAergic and project to mesopontine raphe and tegmentum. Optogenetic stimulation of Chrna5-expressing IPN neurons is aversive, but only after priming by recent prior stimulation or nicotine exposure. The Chrna5Cre transgenic mice revealed that Chrna5 transcription is regulated independently from the Chrna3/b4 genes transcribed on the opposite strand.\",\n      \"method\": \"Electrophysiology in α5-null mice; BAC recombineering to generate Chrna5Cre transgenic mice; optogenetics; reporter-based circuit tracing; immunohistochemistry\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (electrophysiology, optogenetics, transgenic mice, circuit anatomy) in a single rigorous study; direct mechanistic readout\",\n      \"pmids\": [\"29954848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Transgenic rats expressing the human CHRNA5 risk polymorphism (rs16969968, D398N, α5SNP) self-administer more nicotine at high doses and exhibit higher nicotine-induced reinstatement of nicotine seeking than wild-type rats. IPN neurons of α5SNP rats showed altered reactivity to nicotine electrophysiologically, linking the IPN circuit to the higher relapse phenotype.\",\n      \"method\": \"Zinc finger nuclease-generated knock-in rats; intravenous nicotine self-administration; reinstatement paradigm; ex vivo electrophysiology of IPN neurons\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — knock-in rat model with specific human variant, complemented by electrophysiology and behavioral paradigms; multiple orthogonal methods in one study\",\n      \"pmids\": [\"30293722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Transgenic mice overexpressing the human CHRNA5/A3/B4 genomic cluster showed increased functional α3β4-nAChRs in brain regions where these subunits are normally expressed, increased sensitivity to pharmacological effects of nicotine, higher activation of the medial habenula and reduced activation of dopaminergic VTA neurons after acute nicotine, and increased acquisition of nicotine self-administration with a differential response in a progressive ratio test.\",\n      \"method\": \"BAC transgenic mouse overexpression; radioligand binding for α3β4-nAChRs; pharmacological nicotine challenge; c-Fos immunostaining; nicotine self-administration; progressive ratio test\",\n      \"journal\": \"Amino acids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic gain-of-function model with multiple orthogonal behavioral and neurobiological readouts; in vivo mechanistic study\",\n      \"pmids\": [\"22101982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"iPSC-derived human dopaminergic and glutamatergic neurons carrying the CHRNA5 N398 risk allele (rs16969968) showed increased excitatory postsynaptic current responses to nicotine compared to D398 neurons. N398 glutamatergic neurons responded to lower nicotine doses (0.1 μM) with greater frequency and amplitude but also exhibited rapid desensitization, consistent with prior functional characterizations of the N398-associated receptor.\",\n      \"method\": \"iPSC differentiation to dopaminergic and glutamatergic neurons from homozygous D398 or N398 donors; whole-cell electrophysiology; gene expression profiling\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional electrophysiology in human iPSC-derived neurons with isogenic-like genotype comparison; two neuron types tested; single lab, multiple methods\",\n      \"pmids\": [\"27698409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Chrna5 is essential for the rapid onset of postsynaptic cholinergic responses in prefrontal cortex layer VI corticothalamic neurons: optogenetic stimulation of cholinergic afferents in Chrna5 knockout mice showed slowed and delayed nicotinic excitation compared to wild-type. Chrna5 also protects nicotinic responses against desensitization under sustained stimulation conditions. An agonist for the α-α nicotinic binding site (NS9283) allosterically restored the rapid-onset kinetics without triggering desensitization.\",\n      \"method\": \"Optogenetics combined with ex vivo electrophysiology in compound-transgenic Chrna5 knockout and wild-type mice; two independent optogenetic mouse lines; pharmacological rescue with NS9283\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — optogenetics + electrophysiology in two independent transgenic lines with genetic knockout and pharmacological rescue; multiple orthogonal approaches in one rigorous study\",\n      \"pmids\": [\"32817066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Chrna5 genotype determines the lasting effects of developmental in vivo nicotine exposure on prefrontal cortex layer VI neuron morphology and nAChR currents: in wildtype mice, developmental nicotine exposure produced an immature morphological phenotype (apical dendrite morphology) and reduced nAChR currents persisting into adulthood; in α5(-/-) mice, developmental nicotine tended to normalize adult morphology and nAChR currents. Thus α5 subunit incorporation into α4β2* nAChRs in prefrontal layer VI mediates the direction of nicotine teratogenesis.\",\n      \"method\": \"In vivo developmental nicotine exposure in wildtype and Chrna5 knockout mice; patch-clamp electrophysiology; morphometric analysis of prefrontal layer VI neurons\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout combined with developmental exposure, electrophysiology and morphometry; multiple readouts; single lab\",\n      \"pmids\": [\"24055499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Chrna5-expressing neurons in the prefrontal cortex include a distinct population of acetylcholine super-responders with subplate identity. Single-cell transcriptomics revealed that Chrna5+ super-responders uniquely express GPI-anchored lynx prototoxin genes (Lypd1, Ly6g6e, Lypd6b), predicting distinct regulation of nicotinic receptors. Pharmacological manipulation of lynx regulation was developed from transcriptomic predictions.\",\n      \"method\": \"Complex transgenic Chrna5Cre mice; opto-physiological experiments; single-cell RNA sequencing; pharmacological manipulation\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — transgenic mouse opto-physiology combined with single-cell transcriptomics and pharmacology; multiple orthogonal methods in one study\",\n      \"pmids\": [\"36798433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Transgenic rats expressing the human CHRNA5 α5SNP (rs16969968) consumed more alcohol and exhibited increased relapse to alcohol seeking after abstinence. Higher relapse to alcohol was associated with altered neuronal activity in the insula (measured by c-Fos immunostaining). Relapse to food seeking was also increased in α5SNP transgenic rats, and nicotine treatment reduced relapse in both transgenic and control rats.\",\n      \"method\": \"Transgenic knock-in rats (α5SNP); alcohol self-administration; reinstatement paradigm; c-Fos immunostaining; food seeking assay; nicotine treatment\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knock-in rat model with specific human variant; multiple behavioral paradigms and circuit-level readout; single lab\",\n      \"pmids\": [\"31288250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The genomic structure of CHRNA5 was determined: the gene contains multiple exons, and its 3'-UTR region partially overlaps in a tail-to-tail configuration with the 3'-UTR of CHRNA3 due to two previously unknown introns in CHRNA3. Four novel intragenic polymorphisms were identified and characterized in the CHRNA5/A3/B4 cluster.\",\n      \"method\": \"Genomic sequencing; exon-intron structure analysis; polymorphism identification\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct sequence-based determination of genomic structure; foundational structural characterization; single lab\",\n      \"pmids\": [\"11721883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The CHRNA5 rs16969968 A (N398) risk allele in humans was associated with significantly lower ratings of aversive effects of intravenous nicotine (P<5×10⁻⁸), with marked specificity over pleasurable and stimulatory effects. The risk allele was also associated with greater improvement on the Stroop cognitive control task following nicotine administration. This effect was replicated in both European-American and African-American subjects.\",\n      \"method\": \"Intravenous nicotine challenge in human subjects (n=192); subjective ratings of nicotine effects; Stroop cognitive task; genotype-stratified analysis\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — controlled IV nicotine challenge in humans with two independent ancestry groups as internal replication; genome-wide significant p-value; multiple behavioral readouts\",\n      \"pmids\": [\"25948103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The CHRNA5 D398N variant interacts with developmental nicotine exposure in mice: offspring of dams exposed to nicotine during development showed genotype-dependent differences in nicotine intake at weaning; N Nic (N398 + developmental nicotine) offspring consumed the most nicotine at the highest concentration, while D Nic (D398 + developmental nicotine) offspring consumed the least. Nicotine-stimulated dopamine release from striatal synaptosomes was increased in D Nic offspring but decreased in N Nic offspring relative to genotype-matched controls.\",\n      \"method\": \"Two-bottle choice nicotine consumption test; synaptosome nicotine-stimulated dopamine release assay; developmental nicotine exposure paradigm; D398N knock-in mice\",\n      \"journal\": \"Genes, brain, and behavior\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knock-in mouse model with gene-environment interaction design; behavioral and neurochemical readouts; single lab\",\n      \"pmids\": [\"29573323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Nicotine activates CHRNA5 in head and neck squamous cell carcinoma (HNSC) cells to promote proliferation, migration, and invasion. CHRNA5 knockdown reduced these effects, while nicotine reversed them. CHRNA5 activation by nicotine regulates CES1 expression and downstream MEK/ERK signaling: CHRNA5 knockdown decreased p-MEK/MEK, p-ERK/ERK, and CES1 protein levels. Co-immunoprecipitation and molecular docking confirmed a physical interaction between CHRNA5 and CES1. Tumor formation was reduced in nude mice using sh-CHRNA5 Cal27 cells.\",\n      \"method\": \"CCK-8 proliferation assay; wound healing and Transwell migration/invasion assays; siRNA knockdown and overexpression; immunofluorescence; co-immunoprecipitation; molecular docking; western blot for MEK/ERK; transcriptomics/pathway enrichment; in vivo tumor formation assay; IHC in patient tissues\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods; single lab; co-IP and in vivo tumor assay support mechanistic claim\",\n      \"pmids\": [\"39472448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHRNA5 regulates YAP activity in hepatocellular carcinoma (HCC): both in vitro and in vivo assays showed CHRNA5 modulates HCC proliferation through YAP. CHRNA5 also promotes HCC stemness by upregulating Nanog, Sox2, and OCT4, and enhances metastasis by regulating EMT-associated genes. CHRNA5 knockdown or overexpression modulated sorafenib sensitivity in HCC cells.\",\n      \"method\": \"In vitro cell proliferation, migration, invasion assays; YAP activity measurement; stemness gene expression analysis; EMT marker analysis; in vivo xenograft; drug sensitivity assay\",\n      \"journal\": \"Pharmaceutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional assays with loss- and gain-of-function; single lab; mechanistic link to YAP pathway established by functional readout\",\n      \"pmids\": [\"35214008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHRNA5 promotes psoriasis-like inflammation: Chrna5 knockout mice showed significantly reduced severity in an imiquimod-induced psoriasis model. Mechanistically, Chrna5 knockout regulated inflammation through the MAPK kinase kinase-1/c-Jun N-terminal kinase–MAPK/NF-κB pathway. Single-cell sequencing revealed that after Chrna5 knockout, the keratinocyte subpopulation was reduced and Jak/STAT signaling was downregulated. Silencing CHRNA5 in human keratinocytes inhibited proliferation and migration.\",\n      \"method\": \"Chrna5 knockout mice; imiquimod-induced psoriasis model; single-cell RNA sequencing; western blot for MAPK/NF-κB pathway; siRNA knockdown in human keratinocytes; proliferation and migration assays\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo knockout model complemented by single-cell transcriptomics and in vitro knockdown; multiple readouts; single lab\",\n      \"pmids\": [\"35513071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHRNA5 siRNA knockdown in MCF7 breast cancer cells reduced cell viability and DNA synthesis, indicating G1 cell cycle arrest, and increased apoptotic sub-G1 population. Mechanistically, CHRNA5 depletion decreased phosphorylated RB (Ser807/811), increased the BAX/BCL2 ratio, and reduced total and phosphorylated CHEK1 (Ser345). Co-exposure to topoisomerase inhibitors with CHRNA5 siRNA enhanced chemosensitivity, potentially due to reduced DNA damage response.\",\n      \"method\": \"siRNA knockdown; cell viability (CCK-8 equivalent); flow cytometry cell cycle analysis; western blot for RB, BAX, BCL2, CHEK1; gene expression microarray; topoisomerase inhibitor co-treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional and molecular readouts following RNAi; correlation with CHEK1 expression validated in external datasets; single lab\",\n      \"pmids\": [\"30543688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nicotine downregulates JWA expression via the CHRNA5-mediated AKT pathway in lung cancer cells: CHRNA5 knockdown reduced AKT signaling, leading to lower JWA expression, which in turn enhanced CD44 expression through inhibition of SP1 ubiquitination-mediated degradation, promoting lung cancer cell stemness (colony and spheroid formation) and progression. This pathway was validated in vivo, with JAC4 inhibiting nicotine-triggered tumor progression through the JWA/SP1/CD44 axis.\",\n      \"method\": \"GSEA; siRNA knockdown; western blot for AKT, p-AKT, SP1, CD44; ubiquitination assay; colony and spheroid formation assays; in vivo tumor xenograft\",\n      \"journal\": \"Ecotoxicology and environmental safety\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway delineated with multiple functional assays and in vivo validation; single lab, multiple complementary approaches\",\n      \"pmids\": [\"37224781\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CHRNA5 encodes the α5 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), which assembles into heteromeric receptors (e.g., α4β2α5, α3β4α5) to modulate cholinergic signaling: in the prefrontal cortex, α5-containing receptors mediate rapid-onset cholinergic excitation of corticothalamic layer VI neurons and protect against desensitization; in the interpeduncular nucleus, α5-containing receptors mediate nicotine aversion via GABAergic neurons that project to mesopontine raphe and tegmentum; the common risk variant rs16969968 (D398N) reduces aversive responses to nicotine (demonstrated by IV nicotine challenge in humans and electrophysiology in transgenic rodents), increases nicotine and alcohol self-administration and relapse, and causes rapid desensitization of nicotinic currents in human iPSC-derived neurons; CHRNA5 expression is controlled by promoter haplotypes and cis-regulatory variants that alter mRNA levels through changes in DNA methylation and transcription factor binding (including SP1 and ASCL1 in SCLC); in cancer cells, CHRNA5 acts as a positive regulator of proliferation, migration, invasion, and drug resistance through downstream pathways including MEK/ERK, AKT/JWA/SP1/CD44, YAP, and MAPK/NF-κB signaling, while in normal bronchial cells it acts as a negative regulator of nicotine-induced motility.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CHRNA5 encodes the α5 subunit of neuronal nicotinic acetylcholine receptors, which incorporates into heteromeric receptors to shape cholinergic and nicotine-driven signaling across distinct neural circuits and to modulate proliferative signaling in epithelial and cancer cells [#6, #10]. In the prefrontal cortex, α5 is essential for the rapid onset of postsynaptic nicotinic excitation in layer VI corticothalamic neurons and protects these responses from desensitization, an effect allosterically restored by the α-α site agonist NS9283 [#10]; α5 incorporation into α4β2* receptors in this circuit also determines the direction of developmental nicotine teratogenesis on neuronal morphology and currents [#11]. In the interpeduncular nucleus, Chrna5-expressing GABAergic neurons projecting to mesopontine raphe and tegmentum mediate the aversive valence of nicotine [#6]. The common coding variant rs16969968 (D398N) is a central functional determinant: it reduces aversive subjective responses to intravenous nicotine in humans [#15], increases nicotine and alcohol self-administration and relapse in knock-in rodents with altered IPN reactivity [#7, #13], and confers increased excitatory responses with rapid desensitization in human iPSC-derived neurons [#9]. CHRNA5 expression is governed by 5' promoter haplotypes and cis-regulatory variants acting through SP1 binding, ASCL1 transcription, and DNA methylation, with low-expression haplotypes tracking nicotine-dependence and lung-cancer risk [#1, #2, #3, #5]. In cancer, CHRNA5 functions as a positive regulator of proliferation, migration, invasion, and drug resistance through MEK/ERK signaling and a physical interaction with CES1 in head and neck carcinoma [#17], YAP-dependent proliferation and stemness in hepatocellular carcinoma [#18], and an AKT/JWA/SP1/CD44 axis in lung cancer [#21], whereas in non-transformed bronchial cells it acts as a negative regulator of nicotine-induced motility [#0].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing the genomic architecture of CHRNA5 was the prerequisite for any regulatory or variant analysis, defining its exon-intron structure and its tail-to-tail 3'-UTR overlap with CHRNA3 within the clustered locus.\",\n      \"evidence\": \"Genomic sequencing and exon-intron structure analysis with polymorphism identification across the CHRNA5/A3/B4 cluster\",\n      \"pmids\": [\"11721883\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not assign function to the identified polymorphisms\", \"No expression or receptor-assembly data\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Two studies addressed how CHRNA5 transcription is controlled, showing the clustered subunit genes are coordinately driven by ASCL1 in SCLC and that 5' promoter haplotypes set CHRNA5 mRNA levels in lung tissue.\",\n      \"evidence\": \"siRNA knockdown of ASCL1 with qRT-PCR in lung cancer lines; qRT-PCR on human lung tissue plus luciferase reporter assays across four lung cancer cell lines\",\n      \"pmids\": [\"20124469\", \"20733116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ASCL1 knockdown effect shown for CHRNA3/B4, not direct CHRNA5 transcription\", \"Did not identify the specific causal promoter nucleotides\", \"No link to receptor function\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Reporter-based dissection of promoter variants identified loss of an SP1 site and a distal repressor element as cis-regulatory mechanisms, mapping how risk alleles lower CHRNA5 expression.\",\n      \"evidence\": \"Luciferase reporter assays in neuroblastoma cells with allelic expression imbalance analysis in post-mortem brain\",\n      \"pmids\": [\"21858091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SP1 binding inferred from sequence, not directly demonstrated\", \"Reporter assays in heterologous cells may not reflect endogenous chromatin\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Functional studies in epithelial cells revealed an unexpected role for CHRNA5 as a brake on nicotine-induced motility, distinguishing its behavior in normal bronchial cells from its later pro-tumorigenic roles.\",\n      \"evidence\": \"siRNA knockdown and α-conotoxin MII inhibition with motility, invasion, and calcium influx assays in bronchial and lung cancer cells\",\n      \"pmids\": [\"21586512\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking α5 loss to CHRNA7-dependent motility unresolved\", \"Single lab; effects on adhesion molecules correlative\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Gain-of-function overexpression of the human gene cluster in mice established that altered subunit dosage changes nicotine sensitivity, habenular/VTA circuit activation, and self-administration.\",\n      \"evidence\": \"BAC transgenic overexpression with radioligand binding, c-Fos imaging, and nicotine self-administration\",\n      \"pmids\": [\"22101982\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cluster overexpression cannot isolate CHRNA5-specific contribution\", \"Did not test the rs16969968 variant\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Quantitative allele-specific expression in human brain demonstrated that cis-regulatory variants act directly on CHRNA5 transcript levels in the cortex, extending the regulatory mechanism from lung/cancer cells to relevant neural tissue.\",\n      \"evidence\": \"Allele-specific gene expression in post-mortem frontal cortex from two ancestral populations\",\n      \"pmids\": [\"24303001\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"10 correlated variants could not be resolved to a single causal site\", \"No functional receptor readout\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A genetic-knockout developmental study showed that α5 incorporation into prefrontal α4β2* receptors dictates the direction of nicotine teratogenesis, providing a circuit-level mechanism for α5-dependent vulnerability.\",\n      \"evidence\": \"Developmental nicotine exposure in wildtype and Chrna5 knockout mice with patch-clamp electrophysiology and morphometry of layer VI neurons\",\n      \"pmids\": [\"24055499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the morphological reversal in knockouts not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Two studies tied the rs16969968 risk allele and a methylation-controlling SNP to human phenotype, showing the N398 allele blunts nicotine aversion and that lower CHRNA5 methylation/expression increases dependence risk.\",\n      \"evidence\": \"Intravenous nicotine challenge in humans of two ancestries; cis-meQTL across four brain regions and haplotype association in five cohorts (N=11,096)\",\n      \"pmids\": [\"25948103\", \"26220977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-level mechanism of blunted aversion not addressed in the human challenge study\", \"Causal direction between methylation and expression inferred from association\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Human iPSC-derived neurons provided a cell-autonomous readout, showing the N398 allele increases nicotine-evoked excitatory currents but accelerates desensitization, connecting genotype to receptor biophysics in human cells.\",\n      \"evidence\": \"Whole-cell electrophysiology in iPSC-derived dopaminergic and glutamatergic neurons from D398 versus N398 donors\",\n      \"pmids\": [\"27698409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Donor lines not isogenic\", \"Single lab; receptor subunit composition not directly resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Circuit-resolving studies localized α5 function to GABAergic IPN neurons mediating nicotine aversion and showed the human risk variant alters IPN reactivity and increases nicotine self-administration and relapse in knock-in rats.\",\n      \"evidence\": \"Chrna5-null electrophysiology, Chrna5Cre BAC transgenics, optogenetics and circuit tracing in mice; zinc-finger-nuclease knock-in rats with self-administration, reinstatement, and IPN electrophysiology\",\n      \"pmids\": [\"29954848\", \"30293722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream targets of the IPN-to-raphe/tegmentum projection not mapped\", \"Priming requirement for aversion mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A gene-environment knock-in study showed D398N interacts with developmental nicotine exposure to set later nicotine intake and striatal dopamine release, demonstrating allele-dependent reprogramming.\",\n      \"evidence\": \"Two-bottle choice consumption and striatal synaptosome dopamine-release assays in D398N knock-in mice with developmental exposure\",\n      \"pmids\": [\"29573323\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mediator of the divergent dopamine response unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Subsequent work refined the cortical role, identifying Chrna5+ acetylcholine super-responder neurons of subplate identity defined by lynx prototoxin gene expression, and extended the variant's behavioral reach to alcohol and food relapse.\",\n      \"evidence\": \"Chrna5Cre opto-physiology with single-cell RNA-seq and pharmacology; α5SNP knock-in rats with alcohol/food reinstatement and c-Fos imaging\",\n      \"pmids\": [\"36798433\", \"31288250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional necessity of lynx prototoxins for α5 regulation not directly tested\", \"Insula c-Fos correlation does not establish causality\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Optogenetic interrogation defined the kinetic role of α5 in prefrontal layer VI: it confers rapid-onset nicotinic excitation and desensitization resistance, with pharmacological rescue pinpointing the α-α binding site.\",\n      \"evidence\": \"Optogenetics plus ex vivo electrophysiology in two independent Chrna5 knockout transgenic lines with NS9283 rescue\",\n      \"pmids\": [\"32817066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo behavioral consequence of altered kinetics not tested\", \"Receptor stoichiometry underlying the kinetic effect inferred pharmacologically\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A series of cancer studies established CHRNA5 as a nicotine-activated positive regulator of tumor cell proliferation, invasion, stemness, and drug resistance through distinct downstream pathways across tumor types and an inflammatory tissue.\",\n      \"evidence\": \"RNAi/overexpression with proliferation, migration, cell-cycle and xenograft assays plus co-IP/docking (HNSC, CES1/MEK-ERK; HCC, YAP; lung, AKT/JWA/SP1/CD44; breast, RB/CHEK1) and Chrna5 knockout in an imiquimod psoriasis model\",\n      \"pmids\": [\"39472448\", \"35214008\", \"37224781\", \"30543688\", \"35513071\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether tumor effects require canonical ion-channel activity of α5 is unresolved\", \"CES1 co-IP not reciprocally validated; pathways delineated largely in single labs\", \"Reconciliation with the negative-regulator role in bronchial cells unaddressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the receptor-level kinetic and desensitization phenotypes conferred by α5 and the D398N variant translate into the specific behavioral and circuit-level changes, and how the same subunit acts as a motility brake in normal epithelium yet a pro-tumorigenic signaling node in cancer, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying mechanism linking ion-channel function to the cancer signaling pathways\", \"Stoichiometry and partner-subunit dependence of α5 across tissues not systematically resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [6, 10, 9]},\n      {\"term_id\": \"GO:0005216\", \"supporting_discovery_ids\": [10, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 9, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [6, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 18, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 5]}\n    ],\n    \"complexes\": [\n      \"α4β2α5 nicotinic acetylcholine receptor\",\n      \"α3β4α5 nicotinic acetylcholine receptor\"\n    ],\n    \"partners\": [\n      \"CES1\",\n      \"CHRNA3\",\n      \"CHRNB4\",\n      \"CHRNA4\",\n      \"CHRNB2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}